Donation type and the effect of pre-transplant donor specific antibodies - Data from the Swiss Transplant Cohort Study.

ABMR DBD DCD donor specific antibodies graft loss kidney transplantation living donation virtual cross-match

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 21 11 2022
accepted: 30 01 2023
entrez: 6 3 2023
pubmed: 7 3 2023
medline: 8 3 2023
Statut: epublish

Résumé

The type of donation may affect how susceptible a donor kidney is to injury from pre-existing alloimmunity. Many centers are, therefore, reluctant to perform donor specific antibody (DSA) positive transplantations in the setting of donation after circulatory death (DCD). There are, however, no large studies comparing the impact of pre-transplant DSA stratified on donation type in a cohort with a complete virtual cross-match and long-term follow-up of transplant outcome. We investigated the effect of pre-transplant DSA on the risk of rejection, graft loss, and the rate of eGFR decline in 1282 donation after brain death (DBD) transplants and compared it to 130 (DCD) and 803 living donor (LD) transplants. There was a significant worse outcome associated with pre-transplant DSA in all of the studied donation types. DSA directed against Class II HLA antigens as well as a high cumulative mean fluorescent intensity (MFI) of the detected DSA showed the strongest association with worse transplant outcome. We could not detect a significant additive negative effect of DSA in DCD transplantations in our cohort. Conversely, DSA positive DCD transplants appeared to have a slightly better outcome, possibly in part due to the lower mean fluorescent intensity (MFI) of the pre-transplant DSA. Indeed when DCD transplants were compared to DBD transplants with similar MFI (<6.5k), graft survival was not significantly different. Our results suggest that the negative impact of pre-transplant DSA on graft outcome could be similar between all donation types. This suggests that immunological risk assessment could be performed in a similar way regardless of the type of donor kidney transplantation.

Identifiants

pubmed: 36875145
doi: 10.3389/fimmu.2023.1104371
pmc: PMC9974644
doi:

Substances chimiques

Antibodies 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1104371

Investigateurs

Patrizia Amico (P)
Andres Axel (A)
John David Aubert (JD)
Vanessa Banz (V)
Beckmann Sonja (B)
Guido Beldi (G)
Christoph Berger (C)
Ekaterine Berishvili (E)
Isabelle Binet (I)
Pierre-Yves Bochud (PY)
Sanda Branca (S)
Heiner Bucher (H)
Thierry Carrel (T)
Emmanuelle Catana (E)
Yves Chalandon (Y)
Sabina De Geest (S)
Olivier De Rougemont (O)
Michael Dickenmann (M)
Joëlle Lynn Dreifuss (JL)
Michel Duchosal (M)
Thomas Fehr (T)
Sylvie Ferrari-Lacraz (S)
Nicola Franscini (N)
Christian Garzoni (C)
Paola Gasche Soccal (PG)
Christophe Gaudet (C)
Déla Golshayan (D)
Nicolas Goossens (N)
Karine Hadaya (K)
Jörg Halter (J)
Dominik Heim (D)
Christoph Hess (C)
Sven Hillinger (S)
Hans Hirsch (H)
Patricia Hirt (P)
Günther Hofbauer (G)
Uyen Huynh-Do (U)
Franz Immer (F)
Michael Koller (M)
Mirjam Laager (M)
Bettina Laesser (B)
Roger Lehmann (R)
Alexander Leichtle (A)
Christian Lovis (C)
Oriol Manuel (O)
Hans-Peter Marti (HP)
Pierre Yves Martin (PY)
Michele Martinelli (M)
Valérie McLin (V)
Katell Mellac (K)
Aurelia Mercay (A)
Karin Mettler (K)
Nicolas Mueller (N)
Antonia Müller (A)
Thomas Müller (T)
Ulrike Müller-Arndt (U)
Beat Müllhaupt (B)
Mirjam Nägeli (M)
Graziano Oldani (G)
Manuel Pascual (M)
Klara Posfay-Barbe (K)
Juliane Rick (J)
Anne Rosselet (A)
Simona Rossi (S)
Silvia Rothlin (S)
Frank Ruschitzka (F)
Urs Schanz (U)
Stefan Schaub (S)
Aurelia Schnyder (A)
Macé Schuurmans (M)
Thierry Sengstag (T)
Federico Simonetta (F)
Katharina Staufer (K)
Susanne Stampf (S)
Jürg Steiger (J)
Guido Stirniman (G)
Ueli Stürzinger (U)
Christian Van Delden (C)
Jean-Pierre Venetz (JP)
Jean Villard (J)
Julien Vionnet (J)
Madeleine Wick (M)
Markus Wilhlem (M)
Patrick Yerly (P)

Informations de copyright

Copyright © 2023 de Rougemont, Deng, Frischknecht, Wehmeier, Villard, Ferrari-Lacraz, Golshayan, Gannagé, Binet, Wirthmueller, Sidler, Schachtner, Schaub, Nilsson and the Swiss Transplant Cohort Study.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Kidney Int. 2000 Aug;58(2):859-66
pubmed: 10916111
Am J Transplant. 2018 Feb;18(2):293-307
pubmed: 29243394
Transplantation. 2019 Sep;103(9):e273-e280
pubmed: 31205266
Kidney Int. 2015 Aug;88(2):241-9
pubmed: 25786101
Transpl Int. 2002 Jan;15(1):10-6
pubmed: 11875607
Am J Transplant. 2018 Sep;18(9):2274-2284
pubmed: 29464832
Lancet. 2010 Oct 16;376(9749):1303-11
pubmed: 20727576
Lancet. 2017 May 27;389(10084):2152-2162
pubmed: 28561006
Int J Surg. 2021 Aug;92:106021
pubmed: 34256169
Transplantation. 1990 Jan;49(1):201-7
pubmed: 2105546
Transplant Proc. 2020 Jan - Feb;52(1):42-49
pubmed: 31901321
J Am Soc Nephrol. 2010 Aug;21(8):1398-406
pubmed: 20634297
Nephrol Dial Transplant. 2006 Jun;21(6):1689-96
pubmed: 16490743
J Am Soc Nephrol. 2019 Dec;30(12):2413-2425
pubmed: 31597715
Am J Transplant. 2012 Feb;12(2):388-99
pubmed: 22081892
PLoS One. 2020 Jul 29;15(7):e0236662
pubmed: 32726350
Nephrol Dial Transplant. 2019 Jun 1;34(6):1056-1063
pubmed: 30365008
Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1056-1066
pubmed: 31213508
Front Immunol. 2022 Sep 21;13:1005790
pubmed: 36211367
Clin Transplant. 2018 Mar;32(3):e13190
pubmed: 29314286
J Am Soc Nephrol. 2019 Nov;30(11):2262-2274
pubmed: 31653784
N Engl J Med. 2018 Sep 20;379(12):1150-1160
pubmed: 30231232
Am J Transplant. 2017 Aug;17(8):2092-2102
pubmed: 28245084
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Transpl Int. 2021 Dec;34(12):2755-2768
pubmed: 34561920
Nephrol Dial Transplant. 2022 May 25;37(6):1181-1187
pubmed: 34919732
Transplant Rev (Orlando). 2020 Oct;34(4):100563
pubmed: 32576429
BMC Health Serv Res. 2018 Nov 20;18(1):876
pubmed: 30458762

Auteurs

Olivier de Rougemont (O)

Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Yun Deng (Y)

Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.

Lukas Frischknecht (L)

Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.

Caroline Wehmeier (C)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.

Jean Villard (J)

Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.

Sylvie Ferrari-Lacraz (S)

Transplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.

Déla Golshayan (D)

Transplantation Center, Lausanne University Hospital, Lausanne, Switzerland.

Monique Gannagé (M)

Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Isabelle Binet (I)

Nephrology & Transplantation Medicine, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Urs Wirthmueller (U)

Department of Laboratory Medicine, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Daniel Sidler (D)

Department of Nephrology and Hypertension, Inselspital, Berne University Hospital and University of Berne, Berne, Switzerland.

Thomas Schachtner (T)

Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.

Stefan Schaub (S)

Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.

Jakob Nilsson (J)

Department of Immunology, University Hospital Zurich (USZ), Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH